Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Phase 1

Not yet recruiting

• Conditions: PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Lung Cancer; Pancreatic Cancer Metastatic; Thoracic Cancer; NSCLC; RAS Mutation; MTAP Deletion
• Interventions: Drug: TNG462; Drug: RMC-6236; Drug: RMC-9805

• Registration Number: NCT06922591
• Lead Sponsor: Tango Therapeutics, Inc.

Brief Summary

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805. The study comprises a dose escalation phase and a dose expansion phase.

Detailed Description

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805.

The study will be conducted in patients with MTAP loss and RAS mutant metastatic pancreatic adenocarcinoma (PDAC) or locally advanced or metastatic non-small cell lung cancer (NSCLC) in 2 parts: Phase 1 (dose escalation) and Phase 2 (dose expansion).

Individual Arms in the dose expansion phase may open once the MTD and/or RD(s) has been determined for the corresponding combination in the dose escalation phase of the study.

Study Timeline

• Study First Submitted: 2025-03-28
• Status Verified: 2025-04
• Study First Submitted QC: 2025-04-03
• Study First Posted: 2025-04-10
• Last Update Submitted: 2025-04-11
• Last Update Posted: 2025-04-16
• Study Start: 2025-06
• Primary Completion: 2027-06
• Study Completion: 2027-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 133

Inclusion Criteria

1. Is ≥18 years of age at the time of signature of the main study ICF.
2. Has an ECOG PS of 0 or 1.
3. Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene
4. Has a tumor with a RAS mutation
5. Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC
6. Has received prior standard therapy
7. Must not have received prior RAS-targeted therapy
8. Has evidence of measurable disease based on RECIST v1.1.
9. Adequate organ function
10. Must be able to swallow tablets.
11. Negative pregnancy test at screening
12. Written informed consent must be obtained according to local guidelines

Exclusion Criteria

1. Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor

2. Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805

3. Known allergy, hypersensitivity or intolerance to TNG462, RMC-6236, RMC-9805 or their excipients

4. Has uncontrolled intercurrent illness that will limit compliance with the study requirements.

5. Has an active infection requiring systemic therapy.

6. Is currently participating in or has planned concurrent participation in a study of another investigational agent or device.

7. Has impairment of GI function or disease that may significantly alter the absorption of the oral medications

8. Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms

9. Has current active liver disease from any cause

10. Is known to be HIV positive, unless all the following criteria are met:

    1. CD4+ count ≥300/µL.
    2. Undetectable viral load.
    3. Receiving highly active antiretroviral therapy

11. Has clinically relevant cardiovascular disease

12. History of or presence of active interstitial lung disease

13. Is a female patient who is pregnant or lactating

14. Is unwilling or unable to comply with the scheduled visits, study treatment administration plan, laboratory tests or other study procedures and study restrictions.

15. Has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion may affect the safety of the patient or impair the ability to assess study results

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Dose Escalation 1A	TNG462	Escalating oral doses of TNG462 in combination with oral RMC-6236
Dose Escalation 1A	RMC-6236	Escalating oral doses of TNG462 in combination with oral RMC-6236
Dose escalation 1B	TNG462	Escalating oral doses of TNG462 in combination with oral RMC-9805
Dose escalation 1B	RMC-9805	Escalating oral doses of TNG462 in combination with oral RMC-9805
Dose Expansion 2A	TNG462	Expansion arm at the RDE(s) of oral TNG462 in combination with oral RMC-6236
Dose Expansion 2A	RMC-6236	Expansion arm at the RDE(s) of oral TNG462 in combination with oral RMC-6236
Dose Expansion 2B	TNG462	Expansion arm at the RDE(s) of oral TNG462 in combination with oralRMC-9805
Dose Expansion 2B	RMC-9805	Expansion arm at the RDE(s) of oral TNG462 in combination with oralRMC-9805

Primary Outcome Measures

Name	Time	Method
Phase 1: Maximum Tolerated Dose	21 days	To determine the MTD and RD(s) of TNG462 in combination with RMC-6236 or RMC-9805
Phase 2: Combination Anti-neoplastic Activity	9 weeks	To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236 or RMC-9805 using RECIST 1.1

Secondary Outcome Measures

Name	Time	Method
Phase 1: Combination Anti-neoplastic Activity	9 weeks	To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236 or RMC-9805 using RECIST 1.1
Phase 1 and 2: Cmax of TNG462 and in Combination	21 days	To characterize the Cmax of TNG462 in combination with RMC-6236 or RMC-9805
Phase 1 and 2: Tmax of TNG462 and in Combination	21 days	To characterize the Tmax of TNG462 in combination with RMC-6236 or RMC-9805
Phase 1 and 2: AUC of TNG462 and in Combination	21 days	To characterize the AUC of TNG462 and in combination with RMC-6236 or RMC-9805
Phase 1 and 2 Adverse Event Profile	21 days	To determine the safety and tolerability of TNG462 in combination with RMC-6236 or RMC-9805